We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma.
- Authors
Cai, Xiaobo; Li, Jun; Yuan, Xiaodong; Xiao, Jingbo; Dooley, Steven; Wan, Xinjian; Weng, Honglei; Lu, Lungen
- Abstract
<bold>Background: </bold>CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangiocarcinoma (ICC).<bold>Methods: </bold>Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, TGF-β1, p-Smad2 and epithelial-mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were analyzed.<bold>Results: </bold>IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The CD133+ patients had significantly higher metastasis rate than those without CD133+ tumor cells (36.7% vs. 10.1%, p = 0.03). The CD133+ patients had shorter overall and disease-free survival time as compared to the CD133- patients. Furthermore, 90.9% of CD133+ patients developed cancer recurrence, as compared to 64.3% of CD133- patients (p = 0.02). As compared to CD133- patients, tumor cells in CD133+ patients demonstrated high levels of TGF-β/p-Smad2 as well as EMT-like alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4.<bold>Conclusions: </bold>CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated with TGF-β related EMT alterations.
- Subjects
CHOLANGIOCARCINOMA; PROMININ; GENE expression; TRANSFORMING growth factors; IMMUNOHISTOCHEMISTRY; PROGNOSIS
- Publication
Journal of Translational Medicine, 2018, Vol 16, p1
- ISSN
1479-5876
- Publication type
journal article
- DOI
10.1186/s12967-018-1423-9